Brief: I-Mab To Present Phase 2 Clinical Data Of CD47 Antibody Lemzoparlimab
18/07/2022 13:56
July 18 (Reuters) - I-Mab IMAB.O :
* I-MAB TO PRESENT PHASE 2 CLINICAL DATA OF CD47 ANTIBODY
LEMZOPARLIMAB AT ESMO CONGRESS 2022
Source text for Eikon: ID:nPn5yXF3qa
Further company coverage: IMAB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NovaBridge Biosciences
See all newsBrief: Visara Secures Exclusive Option For Potential Acquisition Of Yol104-2 For Ocular Surface Squamous Neoplasia
Brief: Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis
Brief: Wuhan Hiteck Biological Pharma Grants Visara Exclusive Rights To HT006.2.2 Outside Greater China
Brief: Novabridge Biosciences Announces Expanded Givastomig Safety And Efficacy Data
NovaBridge Biosciences expected to post a loss of 13 cents a share - Earnings Preview